Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.800 | 0.972 | 36 | 2007 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.800 | 0.971 | 35 | 2007 | 2019 | |||||
Familial (FPAH)
|
276 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.030 | 1.000 | 3 | 2012 | 2016 | |||||
Neoplasms
|
1644 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.030 | 1.000 | 3 | 2009 | 2012 | |||||
Carcinoma of Male Breast
|
38 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.020 | 1.000 | 2 | 2013 | 2018 | |||||
estrogen receptor-negative breast cancer
|
40 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.020 | 1.000 | 2 | 2011 | 2013 | |||||
Malignant neoplasm of male breast
|
43 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.020 | 1.000 | 2 | 2013 | 2018 | |||||
Malignant Neoplasms
|
1641 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.020 | 1.000 | 2 | 2012 | 2019 | |||||
Primary malignant neoplasm
|
1374 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.020 | 1.000 | 2 | 2012 | 2019 | |||||
Breast Cancer, Familial
|
91 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Carcinoma, Ovarian Epithelial
|
327 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Early-Stage Breast Carcinoma
|
7 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Laryngeal Squamous Cell Carcinoma
|
30 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Malignant neoplasm of ovary
|
315 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Nasopharyngeal carcinoma
|
320 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.700 | 1.000 | 1 | 2010 | 2010 | |||||
Neoplasm Metastasis
|
327 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Node-negative breast cancer
|
2 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Non-Functioning Pituitary Gland Neoplasm
|
2 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Oestrogen receptor positive breast cancer
|
58 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
ovarian neoplasm
|
757 | 0.695 | 0.360 | 10 | 121592803 | intron variant | A/G | snv | 0.58 | 0.010 | 1.000 | 1 | 2012 | 2012 |